tiprankstipranks
Alterity Therapeutics Advances in Neurodegenerative Drug Trials
Company Announcements

Alterity Therapeutics Advances in Neurodegenerative Drug Trials

Alterity Therapeutics Ltd. (AU:ATH) has released an update.

Don't Miss Our Christmas Offers:

Alterity Therapeutics has made significant strides in 2024 with its lead drug, ATH434, nearing the completion of a pivotal Phase 2 trial for Multiple System Atrophy (MSA). Promising preliminary results and ongoing research bolster its potential in treating neurodegenerative diseases, especially Parkinsonian disorders. As the company anticipates major data releases in 2025, it continues to engage with the scientific community to advance its development programs.

For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyAlterity Therapeutics initiated with a Buy at Maxim
TheFlyAlterity Therapeutics completes last patient visit in ATH434-201 trial
TipRanks Australian Auto-Generated NewsdeskAlterity Therapeutics Advances with ATH434 Trial Completion
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App